Hit enter to search or ESC to close

Author: Alterity Therapeutics

Quarterly Cash Flow Report

Highlights: Results of Phase 1 Clinical Trials for lead compound PBT434 announced Presentation of clinical trial data at the 2019 International Congress of Parkinson’s Disease and Movement Disorders (MDS Congress) in France Presentation at the Janney Healthcare conference in New York Cash balance of $10.7M Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the ...

Alterity presents clinical data on PBT434 at the 2019 MDS Congress

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), presents a poster today titled: A First in Human Study of PBT434, a Novel Small Molecule Inhibitor of α-Synuclein Aggregation at the 2019 International Congress of Parkinson’s Disease and Movement Disorders (MDS Congress) in Nice, France. The poster will present findings from the completed ...

Alterity Therapeutics Presents to Finance News Network

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – June 4, 2019. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is participating in the Finance News Network investor event today in Sydney. The event attracts a large number of retail, high net worth and sophisticated investors. The presentation follows the company’s strong presence at the ...

Alterity Therapeutics commences US investor meetings following positive clinical data

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is today commencing an investor roadshow in the US.  The meetings follow the Company’s presentation of clinical data from its Phase 1 clinical trial program for its investigative drug PBT434 at the American Academy of Neurology Annual Meeting last week. The data indicate that ...